Table 4.
Impact of gender of the participants on the effect of pravastatin on circulating adiponectin: results of subgroup analyses
| Study characteristics | WMD of serum adiponectin concentration (μg/mL) | ||||
|---|---|---|---|---|---|
| Comparisons (patients), n | I2 (%) | WMD (95% CI) | P-valuea | P-valueb | |
| All female participants | |||||
| Yes | 2 (73) | 0 | −0.04 (−1.01, 0.93) | 0.94 | |
| No | 7 (522) | 29 | 0.82 (0.30, 1.34) | 0.002 | 0.13 |
| Median | |||||
| ≤50% | 4 (236) | 0 | 0.01 (−0.73, 0.76) | 0.97 | |
| >50% | 5 (359) | 31 | 1.01 (0.43, 1.59) | <0.001 | 0.04 |
| All male participants | |||||
| Yes | 2 (183) | 60 | 1.41 (0.58, 2.23) | <0.001 | |
| No | 7 (412) | 0 | 0.29 (−0.26, 0.84) | 0.31 | 0.03 |
Notes:
a
P-values for subgroup effects.
b
P-values for subgroup interaction.
Abbreviation: WMD, weighted mean difference.